Hermetica Superfood Encyclopedia
The Short Answer
Madecassoside is a triterpenoid saponin glycoside derived from Centella asiatica, structurally composed of madecassic acid bound to a sugar moiety. It exerts its primary effects by suppressing NF-κB signaling and inhibiting melanogenesis via downregulation of tyrosinase activity, making it relevant for both skin pigmentation and inflammatory conditions.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordmadecassoside benefits
Synergy Pairings3
Madecassoside (Triterpenoid saponin) — botanical close-up
Health Benefits
Origin & History
Natural habitat
Madecassoside is a triterpenoid saponin extracted from Centella asiatica (Gotu Kola), a perennial herbaceous plant native to wetlands in Asia. It belongs to the pentacyclic triterpene glycoside class, derived from asiatic acid, and is typically isolated from the plant's leaves and stems through solvent extraction processes.
“Centella asiatica, the source of madecassoside, has been used in Traditional Chinese Medicine and Ayurvedic systems for centuries to treat skin wounds, inflammation, arthritis, and improve circulation. Madecassoside and asiaticoside are implicated in historical treatments for hypoxic-ischemic brain injuries and various dermatological conditions.”Traditional Medicine
Scientific Research
Human clinical evidence is limited to topical applications showing melanin reduction after 8 weeks and skin barrier improvements with nanoemulsion formulations. Most evidence comes from preclinical models, including a mouse arthritis study (PMID: 19135346) demonstrating anti-inflammatory effects and an obesity model showing metabolic benefits at 40 mg/kg/day oral dosing.
Preparation & Dosage
Traditional preparation
Topical: Concentrations sufficient for melanin reduction over 8 weeks (exact mg not specified in studies). Oral (animal studies): 40 mg/kg/day for 8 weeks showed metabolic effects. In vitro studies used 200-1000 μg/mL. No standardized human oral dosages established. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable", "fat": "Not applicable", "carbohydrates": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"madecassoside": "Concentration not typically quantified in dietary terms; primarily used in topical formulations", "bioavailability": "Limited oral bioavailability; primarily effective in topical applications"}}
How It Works
Mechanism of Action
Madecassoside inhibits the NF-κB signaling pathway, reducing transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6, as well as suppressing cyclooxygenase-2 (COX-2)-driven prostaglandin E2 (PGE2) synthesis. In melanocytes, it downregulates microphthalmia-associated transcription factor (MITF) and tyrosinase enzyme activity, thereby reducing melanin biosynthesis triggered by UV radiation. Additionally, emerging preclinical data suggest it modulates AMPK and PPARγ pathways, which may underlie its proposed metabolic and weight-management effects.
Clinical Evidence
A human clinical trial demonstrated that topical application of madecassoside over 8 weeks produced significant measurable reductions in skin melanin index, though sample sizes remain small and this represents preliminary evidence requiring replication in larger randomized controlled trials. Anti-inflammatory effects have been robustly characterized in rodent and cell-culture models, showing dose-dependent suppression of TNF-α, IL-1β, IL-6, and PGE2, but these have not yet been fully validated in well-powered human studies. Weight management data originate from preclinical investigations at approximately 40 mg dosing contexts, and no large-scale human RCTs currently confirm this application. Overall, the evidence base is promising but remains early-stage for most indications beyond topical skin use.
Safety & Interactions
Topical madecassoside is generally well tolerated, with contact dermatitis reported rarely and primarily in individuals with known Centella asiatica sensitivity. Oral supplementation safety data in humans are limited; high-dose animal studies have not identified significant hepatotoxicity, but caution is warranted given the lack of long-term human trials. Madecassoside may theoretically potentiate immunosuppressive drugs by further reducing cytokine activity, and its COX-2 inhibitory properties could additively interact with NSAIDs. Pregnant and breastfeeding individuals should avoid oral supplementation due to insufficient human safety data, though topical use at cosmetic concentrations is generally considered low risk.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Centella asiatica extract saponinGotu kola triterpenoidAsiatic acid glycosidePentacyclic triterpene glycosideCentella saponinMadecassic acid derivativeBrahmi saponinMandukaparni extract compound
Frequently Asked Questions
How long does madecassoside take to reduce skin pigmentation?
A published human clinical trial showed statistically significant reductions in the melanin index after 8 weeks of consistent topical madecassoside application. Results vary by baseline pigmentation level and UV exposure, and the evidence is still considered preliminary pending larger confirmatory studies.
What is the difference between madecassoside and asiaticoside?
Both are triterpenoid saponins from Centella asiatica, but madecassoside is the glycoside of madecassic acid (which carries an additional hydroxyl group at C-6), while asiaticoside is the glycoside of asiatic acid. This structural difference gives madecassoside comparatively stronger antioxidant and anti-inflammatory potency in some in vitro assays, though both compounds share overlapping mechanisms including NF-κB modulation.
What dose of madecassoside is used for weight management?
Preclinical research has investigated madecassoside at approximately 40 mg dosing in animal models, where it appeared to influence metabolic parameters potentially through AMPK and PPARγ pathway modulation. No established human clinical dosage for weight management currently exists, and this application should be considered experimental until human RCTs are completed.
Can madecassoside reduce inflammation in the body when taken orally?
Preclinical animal and cell-culture studies consistently show that madecassoside suppresses TNF-α, IL-1β, IL-6, and PGE2 via NF-κB and COX-2 inhibition. However, oral bioavailability data in humans are limited, and no large randomized controlled trials have confirmed systemic anti-inflammatory effects in clinical populations, so this application currently rests on indirect evidence.
Is madecassoside safe to use alongside NSAIDs or anti-inflammatory medications?
Madecassoside shares a mechanistic overlap with NSAIDs through COX-2 and prostaglandin E2 suppression, raising the theoretical possibility of additive anti-inflammatory or antiplatelet effects when combined. There are no published human drug-interaction studies, so individuals taking NSAIDs, corticosteroids, or immunosuppressants should consult a healthcare provider before combining these agents.
What is the evidence quality for madecassoside's skin benefits compared to its weight management claims?
Madecassoside has preliminary human clinical evidence for UV-induced pigmentation reduction (8-week topical study showing significant melanin reduction), making it stronger for skincare applications. In contrast, weight management support is based primarily on animal studies in obese mice at 40 mg/kg/day, which have not yet been adequately replicated in human trials, so the evidence quality is considerably lower for this indication.
Who is most likely to benefit from madecassoside supplementation—topical users or oral supplement takers?
Topical users seeking UV-induced pigmentation reduction have the strongest evidence base from human clinical trials, making them the primary beneficiaries. Oral users interested in anti-inflammatory benefits may see effects via TNF-α and IL-6 reduction demonstrated in preclinical models, though human clinical validation remains limited for systemic inflammation.
How does madecassoside's bioavailability differ between topical and oral administration forms?
Topical madecassoside demonstrates measurable efficacy in human skin (8-week studies show melanin reduction), suggesting effective dermal penetration and local bioavailability. Oral bioavailability data are sparse; animal studies used 40 mg/kg/day to activate SIRT1/AMPK pathways, but human absorption, metabolism, and equivalent dosing remain inadequately characterized.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w madecassoside curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
